Imatinib (Glivec)

Ingredients: Imatinib
Dosage Form: Oral tablets
Innovator’s Brand Name: Glivec
Generic Brand Name: Imakin
Generic Manufacturer: Ziska Pharma

Indications:
Imatinib is indicated for the treatment of Philadelphia chromosome‑positive chronic myeloid leukemia (including chronic phase, accelerated phase, and blast crisis), Philadelphia chromosome‑positive acute lymphoblastic leukemia, myeloproliferative/myelodysplastic diseases associated with PDGF‑receptor rearrangements, progressive systemic mastocytosis, hypereosinophilic syndrome/chronic eosinophilic leukemia, and locally advanced or metastatic dermatofibrosarcoma protuberans.

Dosage and Administration:
For adult patients with chronic‑phase CML, the recommended dose is 400 mg orally once daily (some cases may require 600 mg or 800 mg divided doses). For ALL and other indications, adjust dosing according to clinical response. Administer with a large glass of water and with food. For patients with swallowing difficulties, tablets may be dispersed in water or juice prior to administration.

Adverse Reactions:
Common adverse reactions include fluid retention, edema, hematologic toxicity, congestive heart failure, hepatotoxicity, bleeding, gastrointestinal discomfort, and hypothyroidism.

Storage:
Store in a cool, dry place below 30 °C, protected from light, and keep out of reach of children.

Package Insert (Prescribing Information):

Download Link